Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers

References

• Kemper E, Boogerd W, Thuis I, et al. Modulation of the blood–brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours. Cancer Treat Rev 2004;30:415–423
   PubMed Web of Science ®Google Scholar
• Abe T, Hasegawa S, Taniguchi K, et al. Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and doxorubicin in human gliomas cells. Int J Cancer 1994;58:860–864
   PubMed Web of Science ®Google Scholar
• Muldoon L, Neuwelt E. BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. J Neurooncol 2003;65:49–62
   PubMed Web of Science ®Google Scholar
• Merker P, Lewis M, Walker M, Richardson E. Neurotoxicity of doxorubicin (doxorubicin) perfused through the cerebrospinal fluid spaces of the rhesus monkey. Toxicol Appl Pharmacol 1978;44:191–205
   PubMed Web of Science ®Google Scholar
• Neuwelt E, Pagel M, Barnett P, et al. Pharmacology and toxicity of intracarotid doxorubicin administration following osmotic blood-brain barrier modification. Cancer Res 1981;41:4466–4470
   PubMed Web of Science ®Google Scholar
• Ohnishi T, Tamai I, Sakanaka K, et al. In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem Pharmacol 1995;49:1541–1544
   PubMed Web of Science ®Google Scholar
• Shiraki N, Hamada A, Ohmura T, et al. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Biol Pharm Bull 2001;12:555–557
   Google Scholar
• Breedveld P, Beijnen J, Schellens J. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006;27:17–24
   PubMed Web of Science ®Google Scholar
• Park J, Fong P, Lu J, et al. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomed Nanotechnol Biol Med 2009;5:410–418
   PubMed Web of Science ®Google Scholar
• Voulgaris S, Partheni M. Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol 2002;25:60–64
   PubMed Web of Science ®Google Scholar
• Lesniak M, Upadhyay U, Goodwin R, et al. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 2005;25:3825–3831
   PubMed Web of Science ®Google Scholar
• Allen T, Martin F. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004;31:5–15
   PubMed Web of Science ®Google Scholar
• Yoo H, Lee K, Oh J, Park T. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release 2000;68:419–431
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Gibbs A, Hunt C, et al. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release 2007;124:163–171
   PubMed Web of Science ®Google Scholar
• Tanner P, Holtmannspotter M, Tonn J, Goldbrunner R. Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery 2007;61:E880–E882
   Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65–81
   PubMed Web of Science ®Google Scholar
• Xie J, Lei C, Hu Y, et al. Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer. Curr Pharm Des 2010;16:2331–2340
   PubMed Web of Science ®Google Scholar
• Olivier J, Fenart L, Chauvet R, et al. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 1999;16:1836–1842
   PubMed Web of Science ®Google Scholar
• Olivier J, Huertas R, Lee H, et al. Synthesis of pegylated immunonanoparticles. Pharm Res 2002;19:1137–1143
   PubMed Web of Science ®Google Scholar
• Carroll R, Bhatia D, Geldenhuy W, et al. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target 2010;18:665–674
   PubMed Web of Science ®Google Scholar
• Lockman P, Oyewumi M, Koziara J, et al. Brain uptake of thiamine-coated nanoparticles. J Control Release 2003;93:271–282
   PubMed Web of Science ®Google Scholar
• Wang A-J, Jian C-H, Li S-D, et al. Glutathione-based delivery system. Google Patents US 20120046445 A1; 2011
   Google Scholar
• Liang H, Chen Y, Yang L, et al. Glutathione based delivery system for analgesics. Google Patents US 2008/0095836 A1; 2008
   Google Scholar
• Gaillard P, Inventor. Glutathione-based drug delivery system. International Patents PCT Int Appl 52 CODEN: PIXXD2 WO 2010095940 A2 20100826; 2010
   Google Scholar
• Head D, Andrews B, Asenjo J. Epoxy-oxirane activation of PEG for protein ligand coupling. Biotechnol Technol 1989;1:27–32
   Google Scholar
• Gu F, Zhang L, Teply B, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 2008;105:2586–2591
   PubMed Web of Science ®Google Scholar
• Mu L, Feng S. A novel controlled release formulation for anticancer drug paclitaxel (taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 2003;86:33–48
   PubMed Web of Science ®Google Scholar
• Sahoo S, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded NP is mediated via sustained intracellular drug retention. Mol Pharm 2005;2:373–383
   PubMed Web of Science ®Google Scholar
• Rempe R, Cramer S, Huwel S, Galla HJ. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochem Biophys Res Commun 2011;406:64–69
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12:54–61
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3:90–105, 51
   PubMedGoogle Scholar
• Saija A, Princi P, Trombetta D, et al. Changes in the permeability of the blood-brain barrier following sodium dodecyl sulphate administration in the rat. Exp Brain Res 1997;115:546–551
   PubMed Web of Science ®Google Scholar
• Koziara JM, Lockman PR, Allen DD, Mumper RJ. In situ blood-brain barrier transport of nanoparticles. Pharm Res 2003;20:1772–1778
   PubMed Web of Science ®Google Scholar
• Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 2008;105:11613–11618
   PubMed Web of Science ®Google Scholar
• Lynch I, Salvati A, Dawson KA. Protein-nanoparticle interactions: what does the cell see? Nat Nanotechnol 2009;4:546–547
   PubMed Web of Science ®Google Scholar
• Elsaesser A, Howard CV. Toxicology of nanoparticles. Adv Drug Deliv Rev 2012;64:129–137
   PubMed Web of Science ®Google Scholar
• Wang A-J, Jian C-H, Li S-D, et al. Glutathione based delivery system. Google Patents US 8,569,239 B2; 2008
   Google Scholar
• Chaisri W, Hennink WE, Okonogi S. Preparation and characterization of cephalexin loaded PLGA microspheres. Curr Drug Deliv 2009;6:69–75
   PubMedGoogle Scholar
• Yadav KS, Sawant KK. Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation. Curr Drug Deliv 2010;7:51–64
   PubMedGoogle Scholar
• Muthu MS, Singh S. Poly (d, l-lactide) nanosuspensions of risperidone for parenteral delivery: formulation and in-vitro evaluation. Curr Drug Deliv 2009;6:62–68
   PubMedGoogle Scholar
• Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012;14:1–16
   PubMed Web of Science ®Google Scholar
• Russo A, Mitchell J. Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation. Cancer Treat Rep 1985;69:1293–1296
   PubMedGoogle Scholar
• Alshabanah O, Hafex M, Al-Harbi M, et al. Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementatio. Oxid Med Cell Longev 2010;3:428–433
   PubMed Web of Science ®Google Scholar
• Injac R, Radic N, Govedarica B, et al. Acute doxorubicin pulmotoxicity in rats with malignant neoplasm is effectively treated with fullerenol C60(OH)24 through inhibition of oxidative stress. Pharmco Rep 2009;61:335–342
   PubMed Web of Science ®Google Scholar
• Quiles J, Huerta J, Battino M, et al. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002;180:79–95
   PubMed Web of Science ®Google Scholar
• Tanak Y, Takahashi K. Cardiac oxygen radical metabolism in adriamycin-induced cardiotoxicity. Jikeikai Med J 1990;37:253–264
   Google Scholar
• Etame AB, Smith CA, Chan WCW, Rutka JT. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomed: Nanotechnol, Biol Med 2011;7:992–1000
   PubMed Web of Science ®Google Scholar
• Costantino L, Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today 2012;17:367–378
   PubMed Web of Science ®Google Scholar